New Advances in Chemical Research, May 2021. The transformation of simple hydrocarbons into more complex and valuable products via catalytic C–H bond functionalisation has revolutionised modern synthetic chemistry.Application In Synthesis of 3,4-Dihydroquinoxalin-2(1H)-one, In a article, mentioned the application of 59564-59-9, Name is 3,4-Dihydroquinoxalin-2(1H)-one, molecular formula is C8H8N2O
Phosphodiesterase (PDE) 2A inhibitors have emerged as a novel mechanism with potential therapeutic option to ameliorate cognitive dysfunction in schizophrenia or Alzheimer’s disease through upregulation of cyclic nucleotides in the brain and thereby achieve potentiation of cyclic nucleotide signaling pathways. This article details the expedited optimization of our recently disclosed pyrazolo[1,5-a]pyrimidine lead compound 4b, leading to the discovery of clinical candidate 36 (TAK-915), which demonstrates an appropriate combination of potency, PDE selectivity, and favorable pharmacokinetic (PK) properties, including brain penetration. Successful identification of 36 was realized through application of structure-based drug design (SBDD) to further improve potency and PDE selectivity, coupled with prospective design focused on physicochemical properties to deliver brain penetration. Oral administration of 36 demonstrated significant elevation of 3?,5?-cyclic guanosine monophosphate (cGMP) levels in mouse brains and improved cognitive performance in a novel object recognition task in rats. Consequently, compound 36 was advanced into human clinical trials.
One of the oldest and most widely used commercial enzyme inhibitors is aspirin, Application In Synthesis of 3,4-Dihydroquinoxalin-2(1H)-one, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 59564-59-9
Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N174 | ChemSpider